Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

20/20 Biolabs, Inc. - Common Stock (NQ:AIDX)

0.4293 +0.0203 (+4.96%)
Streaming Delayed Price Updated: 2:25 PM EDT, Sep 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,814
Open 0.4599
Bid (Size) 0.4201 (100)
Ask (Size) 0.4293 (2,900)
Prev. Close 0.4090
Today's Range 0.4183 - 0.4599
52wk Range 0.4000 - 50.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
From 20/20 Biolabs Inc.
Via GlobeNewswire

Performance

YTD
-98.2%
-98.2%
1 Month
-30.3%
-30.3%
3 Month
-28.1%
-28.1%
6 Month
-75.9%
-75.9%
1 Year
-98.2%
-98.2%

More News

Read More
News headline image
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
From 20/20 Biolabs Inc.
Via GlobeNewswire
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
What's Going On With 20/20 Biolabs Stock? ↗
Via Benzinga
News headline image
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
From 20/20 Biolabs Inc.
Via GlobeNewswire

Frequently Asked Questions

Is 20/20 Biolabs, Inc. - Common Stock publicly traded?
Yes, 20/20 Biolabs, Inc. - Common Stock is publicly traded.
What exchange does 20/20 Biolabs, Inc. - Common Stock trade on?
20/20 Biolabs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for 20/20 Biolabs, Inc. - Common Stock?
The ticker symbol for 20/20 Biolabs, Inc. - Common Stock is AIDX on the Nasdaq Stock Market
What is the current price of 20/20 Biolabs, Inc. - Common Stock?
The current price of 20/20 Biolabs, Inc. - Common Stock is 0.4293
When was 20/20 Biolabs, Inc. - Common Stock last traded?
The last trade of 20/20 Biolabs, Inc. - Common Stock was at 09/29/26 02:25 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.